Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chandni Valiathan

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Clinical Pharmacology and Therapeutics|September 9, 2024
Partial Residual Plots as an Integrated Model Diagnostic Tool in Model-Based Meta-AnalysisJohn Maringwa, Paul Matthias Diderichsen, Chandni Valiathan
DNA Repair|December 3, 2011
A rapid survival assay to measure drug-induced cytotoxicity and cell cycle effectsChandni Valiathan, Jose L McFaline, Leona D Samson
The Journal of Pharmacy and Pharmacology|September 28, 2016
Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravirRajesh Krishna, Lilly East, Patrick Larson, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 5, 2026
MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied IndicationsMehrdad Javidi, Gregory E Alexander, Teddy Kosoglou, et al.
American Journal of Clinical Oncology|September 11, 2019
Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin IneligibleTomoko Freshwater, Haojie Li, Chandni Valiathan, et al.
NPJ Vaccines|November 5, 2021
A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity dataJulie Dudášová, Regina Laube, Chandni Valiathan, et al.
Biopharmaceutics & Drug Disposition|October 4, 2016
Atazanavir increases the plasma concentrations of 1200 mg raltegravir doseRajesh Krishna, Lilly East, Patrick Larson, et al.
Genes & Development|September 23, 2008
Genomic predictors of interindividual differences in response to DNA damaging agentsRebecca C Fry, J Peter Svensson, Chandni Valiathan, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 16, 2023
Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision makingDavid C Turner, Russ Wada, Helen Zhou, et al.
Plos Genetics|November 28, 2007
Activation of inflammation/NF-kappaB signaling in infants born to arsenic-exposed mothersRebecca C Fry, Panida Navasumrit, Chandni Valiathan, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Clinical Pharmacology and Therapeutics|September 9, 2024
Partial Residual Plots as an Integrated Model Diagnostic Tool in Model-Based Meta-AnalysisJohn Maringwa, Paul Matthias Diderichsen, Chandni Valiathan
DNA Repair|December 3, 2011
A rapid survival assay to measure drug-induced cytotoxicity and cell cycle effectsChandni Valiathan, Jose L McFaline, Leona D Samson
The Journal of Pharmacy and Pharmacology|September 28, 2016
Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravirRajesh Krishna, Lilly East, Patrick Larson, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 5, 2026
MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied IndicationsMehrdad Javidi, Gregory E Alexander, Teddy Kosoglou, et al.
American Journal of Clinical Oncology|September 11, 2019
Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin IneligibleTomoko Freshwater, Haojie Li, Chandni Valiathan, et al.
NPJ Vaccines|November 5, 2021
A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity dataJulie Dudášová, Regina Laube, Chandni Valiathan, et al.
Biopharmaceutics & Drug Disposition|October 4, 2016
Atazanavir increases the plasma concentrations of 1200 mg raltegravir doseRajesh Krishna, Lilly East, Patrick Larson, et al.
Genes & Development|September 23, 2008
Genomic predictors of interindividual differences in response to DNA damaging agentsRebecca C Fry, J Peter Svensson, Chandni Valiathan, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 16, 2023
Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision makingDavid C Turner, Russ Wada, Helen Zhou, et al.
Plos Genetics|November 28, 2007
Activation of inflammation/NF-kappaB signaling in infants born to arsenic-exposed mothersRebecca C Fry, Panida Navasumrit, Chandni Valiathan, et al.
Pageof 2